Molecular tests and target therapies in oncology: recommendations from the Italian workshop.

Abstract

Next-generation sequencing (NGS) and liquid biopsy are new technologies that can allow overall tumor profiling in a single analysis and play an important role in the implementation of precision oncology. However, the lack of guidelines in this setting has limited the development of precision oncology in Italy. This articlesummarizes recommendations for the appropriate use of NGS in tumor gene profiling, as well asaccess to tests and target drugs, that were prepared by a group of key opinion leaders and relevant stakeholders. In particular, the need to create laboratory networks capable of carrying out NGS tests in Italy ishighlighted. It also appears necessary to establish an adequate reimbursement system for NGS tests. However, the expert panel recommendsthat the use of NGS tests in clinical practice should be limited to specific tumor types, based on the number and complexity of biomarkers and the availability of treatments.